Neuropeptide Y1 Receptor-Expressing Neurons in the Lateral Parabrachial Nucleus in Neuropathic Pain
Project Number7F32NS128392-02
Former Number1F32NS128392-01A1
Contact PI/Project LeaderALLEN, HEATHER NOEL
Awardee OrganizationUNIVERSITY OF FLORIDA
Description
Abstract Text
Project Summary
Pain is a complex phenomenon that elicits somatosensory and motor reflexive responses together with marked
and long-lasting changes in emotional and autonomic states. While acute pain provides protection from tissue
damage, chronic or long-lasting pain, provides no protective function and is often incapacitating. Chronic pain
conditions are debilitating to patients, their families, and society by reducing quality of life and creating
enormous financial consequences that total more than 630 billion USD annually for the United States of
America alone. Neuropathic pain is a type of chronic pain that arises from a lesion or disease affecting the
somatosensory system and affects 7-8% of the general population. However, neuropathic pain is poorly
responsive to analgesic drugs, including opioids, and alternative therapeutics for treatment are desperately
needed. The underlying mechanisms of the development and maintenance of neuropathic pain are poorly
understood. A recent wave of high-profile publications implicates the lateral parabrachial nucleus (lPBN) as a
sensory hub for pain and aversion. The PBN is, a small, bilateral, pontine brain structure that has long been
known to receive alarming, noxious, or threatening homeostatic information such as taste aversion,
nociception, or danger cues. Promising preliminary data within the Taylor (UPitt) and Betley (UPenn)
laboratories implicate glutamatergic PBN neurons expressing the neuropeptide Y (NPY) Y1 receptor (Npy1r-
expressing) in the maintenance of neuropathic pain. First, application of a cool (acetone droplet) or light rub
(cotton swab) stimulus to the hindpaw of a mouse following peripheral nerve injury produces significant Fos
activation within Npy1r-expressing PBN neurons. Second, pharmacological inhibition of PBNNpy1r-expressing
neurons via a selective agonist for the NPY Y1 Gi receptor reduces behavioral symptoms of neuropathic pain,
whereas chemogenetic activation of Npy1r-expressing neurons produces conditioned place aversion. Third,
application of a heat stimulus produces calcium transients in PBNNpy1r-expressing neurons assessed via in
vivo fiber photometry. These observations provide the premise for my central hypothesis that the Npy1r-
expressing subset of PBN neurons are necessary for neuropathic pain-like behaviors.
Specific Aim 1 will utilize in vivo fiber photometry and in situ hybridization to assess the activation of PBN
Npy1r-expressing neurons in both sham and neuropathic animals.
Specific Aim 2 will apply both in vivo pharmacology and chemogenetics to inhibit PBN Npy1r-expressing
neurons in sham and neuropathic animals to assess their necessity for the behavioral reflexive (mechanical
and cold) and affective (conditioned place preference) components of pain.
Specific Aim 3 will examine both the anatomy (anatomical tracing) and functional role (inhibitory
chemogenetics) of the supraspinal targets of PBNNpy1r-expressing efferent projections to uncover the specific
ciruit responsible for both the reflexive and affective components of neuropathic pain.
Public Health Relevance Statement
Project Narrative
Neuropathic pain is a debilitating form of chronic pain afflicting millions of patients worldwide but is poorly
responsive to current analgesic therapies. Recent preclinical behavioral data implicates the lateral parabrachial
nucleus of the brainstem in the maintenance of both the behavioral reflexive and affective components of
neuropathic pain. This study uses in vivo and awake moving fiber photometry and in situ fluorescent
hybridization, intraparabrachial pharmacology and chemogenetics, and anatomical tracing combined with
efferent terminal chemogenetic inhibition to ultimately determine if excitatory lateral parabrachial neurons (those
that contain the type 1 receptor for neuropeptide Y) contribute to the behavioral manifestations of neuropathic
pain.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AcetoneAcute PainAffectAffectiveAgonistAmygdaloid structureAnalgesicsAnatomyAnimalsBehaviorBehavioralBehavioral SymptomsBilateralBrainBrain StemBrain regionCalciumCannulasCell NucleusChronicClozapineComplexCuesDataDevelopmentDiseaseEmotionalFamilyFiberFluorescenceFluorescent in Situ HybridizationFormalinFutureGeneral PopulationGeneticGlutamatesGossypiumHypersensitivityHypothalamic structureImplantIn SituIn Situ HybridizationInfusion proceduresInjuryLaboratoriesLateralLesionLightMaintenanceMeasuresMechanicsModelingMolecularMotorMusNeuronsNeuropathyNeuropeptide Y ReceptorNeuropeptidesNociceptionNociceptorsOpioidOxidesPainPathologicPatientsPatternPeripheralPeripheral nerve injuryPersistent painPharmacologyPhotometryPontine structurePublicationsPublishingQuality of lifeResearch PersonnelRodent ModelRoleSensorySocietiesStimulusStructureStructure of paraventricular nucleus of thalamusStructure of terminal stria nuclei of preoptic regionSurgical InjuriesSwabSystemTaste aversionTestingTherapeuticTissuesUnited StatesVeinsViralVirusWithdrawalWritinganatomical tracingawakecareerchronic painchronic painful conditionconditioned place preferenceexcitatory neuronexperimental studyhealingheat stimulusin vivoinsightmidbrain central gray substancenerve injuryneuropeptide Yneuropeptide Y-Y1 receptorpain signalpainful neuropathyparabrachial nucleusperipheral nerve damagepharmacologicpre-clinicalpreferencereceptorresponsesensory stimulusskillssomatosensoryspared nerve
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
969663814
UEI
NNFQH1JAPEP3
Project Start Date
01-September-2023
Project End Date
31-March-2026
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$86,288
Direct Costs
$86,288
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$86,288
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7F32NS128392-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7F32NS128392-02
Patents
No Patents information available for 7F32NS128392-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7F32NS128392-02
Clinical Studies
No Clinical Studies information available for 7F32NS128392-02
News and More
Related News Releases
No news release information available for 7F32NS128392-02
History
No Historical information available for 7F32NS128392-02
Similar Projects
No Similar Projects information available for 7F32NS128392-02